Author/Creator: Gaudreau, Pierre-Olivier - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Gaudreau, Pierre-Olivier

1. A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC). (2021)

Authors:: Nassabein, Rami; Gaudreau, Pierre-Olivier; Belkaid, Wiam; Florescu, Marie; Blais, Normand
Journal:: Cancer treatment and research communications
Issue:: Number 28(2021)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic. (2023)

Authors:: Hanna, Lilian; Moffat, Gordon Taylor; Hopman, Wilma; Gaudreau, Pierre-Olivier; Fung, Andrea S.
Journal:: Cancer treatment and research communications
Issue:: Number 34(2023)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. CD73-adenosine reduces immune responses and survival in ovarian cancer patients. (3rd May 2016)

Authors:: Gaudreau, Pierre-Olivier; Allard, Bertrand; Turcotte, Martin; Stagg, John
Journal:: Oncoimmunology
Issue:: Volume 5:Number 5(2016)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. CD73–adenosine: a next-generation target in immuno-oncology. (February 2016)

Authors:: Allard, David; Allard, Bertrand; Gaudreau, Pierre-Olivier; Chrobak, Pavel; Stagg, John
Journal:: Immunotherapy
Issue:: Volume 8:Number 2(2016:Feb.)
Page Start:: 145
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. CD73–adenosine: a next-generation target in immuno-oncology. (February 2016)

Authors:: Allard, David; Allard, Bertrand; Gaudreau, Pierre-Olivier; Chrobak, Pavel; Stagg, John
Journal:: Immunotherapy
Issue:: Volume 8:Number 2(2016:Feb.)
Page Start:: 145
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. IRECIST and atypical patterns of response to immuno-oncology drugs. Issue 6 (17th June 2022)

Authors:: Ramon-Patino, Jorge Luis; Schmid, Sabine; Lau, Sally; Seymour, Lesley; Gaudreau, Pierre-Olivier; Li, Janice Juan Ning; Bradbury, Penelope Ann; Calvo, Emiliano
Journal:: Journal for immunotherapy of cancer
Issue:: Volume 10:Issue 6(2022)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. (4th May 2019)

Authors:: Gaudreau, Pierre-Olivier; Clairefond, Sylvie; Class, Caleb A.; Boulay, Pierre-Luc; Chrobak, Pavel; Allard, Bertrand; Azzi, Feryel; Pommey, Sandra; Do, Kim-Anh; Saad, Fred; Trudel, Dominique; Young, Marian; Stagg, John
Journal:: Oncoimmunology
Issue:: Volume 8:Number 5(2019)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗